PATENT Attorney Docket No. 442187/PALL

Group Art Unit: Unassigned

Examiner: Unassigned

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BOSCHETTI et al.

U.S. National Phase of PCT/US2005/001304

Application No. Unassigned

Filed: June 16, 2006

For: CHROMATOGRAPHIC MATERIALFOR

THE ABSORPTION OF PROTEINS AT PHYSIOLOGICAL IONIC STRENGTH

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop PCT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

In re Appln. of BOSCHETTI et al. Application No. Unassigned

	within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:						
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).						
	or the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).						
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).						
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.						
Copie	s of the References						
	Copies of the references listed on the enclosed Form 1449 are enclosed herewith.						
\boxtimes	Copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith.						
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).						

In re Appln. of BOSCHETTI et al. Application No. Unassigned

\boxtimes	A copy of the foreign	gn search report is enclos	sed herewith.					
	The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:							
	U.S. APPLI	CATIONS	St	atus (check o	ne)			
TI	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED			
1.	D. 7 H T DIOTITIONS							
2.								
3.					-			
<u>J.</u>			<u> </u>		L			
Staten	nent under 37 CFR	1.97(e)						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.							
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.							
Statement under 37 CFR 1.704(d)								
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.							
Fees a	and Method of Payr	nent of Fees						
		the applicant(s). Account No. 12-1216 in ate copy of this commun						

IAP12 Rec'd PCT/PTO 1 3 JUN 2006

In re Appln. of BOSCHETTI et al. Application No. Unassigned

Authorization to Charge Additional Fees

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

Credit Account No. 12-1216. Refund

Respectfully submitted,

Jeremy M. Jay, Reg. No. 33,587 LEYDIG, VOIT & MAYER

700 Thirteenth Street, N.W., Suite 300

Washington, DC 20005-3960 (202) 737-6770 (telephone) (202) 737-6776 (facsimile)

IDS (Revised 9/9/05)

4

Please type a p	us sign (+) inside thi	$s box \rightarrow $	+

IAP12 Rec'd PCT/PTO 1 6 JUN 2006

					Complete if Known	
Substitute for for	om 1449A/B/PTO			Application Number	Unassigned	
INE	ORMATION	ו חופכו	OSLIDE	Filing Date	June 16, 2006	
			-	First Named Inventor	Egisto Boschetti	
STATEMENT BY APPLICANT			LICANI	Group Art Unit	Unassigned	
	(Use as many she	eets as nece	ssary)	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	442187/PALL	

			U	S. PATENT DOCUMENTS	<u> </u>	<u></u>				
U.S. Patent Document						U.S. Patent Docu	ıment			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate				
	A 1	3,917,527		Shaltiel	11/4/1975					
	A 2	4,696,980		Porath	9/29/1987					
	A 3	5,075,371		Boschetti et al.	12/24/1991					
	A 4	5,234,991		Tayot et al.	8/10/1993					
·	A 5	5,268,097		Girot et al.	12/7/1993					
	Α6	5,641,870		Rinderknecht et al.	6/24/1997					
··	A7	5,719,060		Hutchens et al.	2/17/1998					
	A 8	5,789,578		Burton et al.	8/4/1998					
	Α9	6,124,137		Hutchens et al.	9/26/2000					
	A 1 0	6,225,047		Hutchens et al.	5/1/2001					
	A 1 1	2004/0124149		Boschetti et al.	7/1/2004					
						 				

FOREIGN Foreign Patent Document					Translation			
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	A12	EP	0 165 912		Jerker Porath	12/27/1985		
	A 1.3	EP	0 180 563		Jerker Porath	5/7/1986		
	A14	wo	92/16292		Lihme et al.	10/1/1992		
	A15	wo	96/00735		Burton et al.	1/11/1996		
	A16	wo	03/064594		Naotaka Kitagawa	8/7/2003		
	A 1 7	wo	2004/024318		Boschetti et al.	3/25/2004		
	A18	wo	2006/043896		Engstrand et al.	4/27/2006		
	A19	GB	2 230 010		Kasche et al.	10/10/1990		

Examiner			Translation	
Initials			Yes	No*+
	A20	BL. Johansson et al., <i>J. Chromatography A</i> , 1016: 21-33 (2003)		
	A21	BL. Johansson et al., <i>J. Chromatography A</i> , 1016:35-49 (2003)		,
	A22	S. C. Burton et al., J. Chromatograph A, 814:71-81 (1998)		
	A23	L. Guerrier et al., Bioseparation, 9:211-221 (2000)		
	A24	G. H. Scholz et al., J. Chromatography B: Biomedical Sciences and Applications, 709:189-196 (1998)		

Evaminas Cianatura	Date Considered	1
Examiner Signature	Date Considered	l i
•		

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).